Published in Cancer Weekly, July 21st, 1997
Despite advances in cancer therapeutics, the mean survival time for patients diagnosed with the central nervous system neoplasm, glioblastoma multiforme, is less than one year. Recent gene therapy approaches to this neoplasm have focused on suicide gene therapy using the herpes simplex virus type-1 thymidine kinase gene followed by the administration of ganciclovir. Although this system shows some promise, its in situ application remains problematic.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.